Diabetes, obesity & metabolismMay 19, 2022

Effectiveness of different doses of tirzepatide compared to semaglutide in type 2 diabetes patients

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Mar 25, 2026

Abstract

Tirzepatide 10 and 15 mg significantly reduced HbA1c by 0.36% and 0.40%, respectively, compared to semaglutide 2 mg.

Tirzepatide 10 mg was associated with a reduction in body weight of -3.15 kg compared to semaglutide 2 mg.
Tirzepatide 15 mg resulted in a body weight reduction of -5.15 kg compared to semaglutide 2 mg.
No significant differences were observed between tirzepatide 5 mg and semaglutide 2 mg for changes in HbA1c and body weight.
The analysis included data from 238 to 240 participants for tirzepatide and 240 participants for semaglutide.

Simplified

AIM: To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes.

MATERIALS AND METHODS: The primary analysis was a Bucher aITC of the change from baseline at week 40 in HbA1c (%) and body weight (kg). Aggregate data from the SURPASS-2 study that met the HbA1c inclusion criterion of the SUSTAIN FORTE study and from SUSTAIN FORTE metformin-only treated patients were used for primary analysis.

RESULTS: The SURPASS-2 refined population comprised 238/245/240 and 240 participants for tirzepatide 5/10/15 mg and semaglutide 1 mg, respectively. The SUSTAIN FORTE metformin-only population comprised 222 and 227 participants for semaglutide 1 and 2 mg, respectively. In this aITC, tirzepatide 10 and 15 mg significantly reduced HbA1c versus semaglutide 2 mg with an estimated treatment difference (ETD) of -0.36% (95% confidence interval [CI] -0.63, -0.09) and -0.4% (95% CI -0.67, -0.13), respectively. Tirzepatide 10 and 15 mg significantly reduced body weight versus semaglutide 2 mg with an ETD of -3.15 kg (95% CI -4.84, -1.46) and -5.15 kg (95% CI -6.85, -3.45), respectively. There were no significant differences between tirzepatide 5 mg and semaglutide 2 mg on change from baseline in HbA1c and body weight.

CONCLUSIONS: In this aITC, HbA1c and weight reductions were significantly greater for tirzepatide 10 and 15 mg versus semaglutide 2 mg and were similar for tirzepatide 5 mg versus semaglutide 2 mg. These findings provide comparative effectiveness insights in the absence of a head-to-head clinical trial.

Key numbers

-0.36%

Decrease in HbA1c with tirzepatide 10 mg

Estimated treatment difference vs. semaglutide 2 mg

-5.15 kg

Decrease in body weight with tirzepatide 15 mg

Estimated treatment difference vs. semaglutide 2 mg

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Effectiveness of different doses of tirzepatide compared to semaglutide in type 2 diabetes patients

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief